IP and Knowledge Management
FEATURED REPORTS
WHAT'S NEW
-
Saving costs and increasing availability with HP, SAP and SUSE LINUX
by Hewlett-Packard Co.
Case study
In this case study, HP helps Infraserv, a site operator for pharmaceutical companies, to maximize system stability and flexibility and ensure a seamless flow of data between the company’s SAP R/3 system and a new SAP portal.
-
Content management streamlines government compliance for pharmaceutical company
by EMC Corp.
Case study
In this case study, EMC Corp.’s content management system streamlines the submission of new drug applications, supports documentation and cuts time to market for approved drugs for Otsuka America Pharmaceutical Co.
REPORTS BY SUBTOPIC
The Impact of Nanotechnology in Drug Delivery: Global Developments, Market ...
White paper
This report will include an overview of nanoenabled drug delivery technologies, commercial applications and information on the companies pursuing them, information on nanotechnology initiatives and regulation in major international markets (North America, EU, Japan, Israel, etc.), as well as eight-year worldwide forecasts on the industry’s anticipated growth and timing thereof.
Pharma Futurology: 2016 and beyond
|AnalystReport|
Pharma Futurology endeavours to provide a bird’s eye view of the pharmaceutical industry, and where it might be in a decade’s time: how pharmaceutical firms will be connected to the wider healthcare ecosystem, and what technologies will glue it together.
The pharmaceutical pricing, reimbursement and prescribing environment in Canada
By Decision Resources Inc.
White paper
This white paper by Decision Resources Inc. presents an overview of the health care system and pharmaceutical market in Canada, including price tests used by the Patented Medicine Prices Review Board (PMPRB) and price guidelines.
Pharmacor: Analyzing the commercial outlook for drugs in R&D
By Decision Resources Inc.
Product collateral
Pharmacor, Decision Resources’ flagship advisory service, analyzes and forecasts the commercial outlook for drugs in research and development.
Spectrum: Intelligence for pharmaceutical and biotechnology decision makers
By Decision Resources Inc.
Product collateral
Spectrum is a comprehensive executive advisory service that identifies and analyzes key business and technology drivers of the pharmaceutical and biotechnology markets. .
Six Future High Growth Areas and the Skill Sets They Will Demand
White paper
This is an excerpt from the upcoming white paper, “The Continuing Evolution of the Pharmaceutical Industry: Career Challenges and Opportunities” by Michael Steiner et al.
The Cost of Quality: Benchmarking Enterprise Quality Management
By Aberdeen Group
White paper
This benchmark study showcases the operational performance benefits manufacturers are currently enjoying due to the adoption of enterprise quality management strategies and technologies.
Price trends for frequently used brand and generic drugs, 2000-2004
By U.S. Government Accountability Office
White paper
This U.S. Government Accountability Office white paper tracked average prices charged at retail pharmacies for drugs. Its conclusion? Prescription drug spending has been the fastest-growing segment of national health expenditures.
What patent owners should consider in filing for a patent term extension
By Sterne Kessler Goldstein & Fox PLLC
White paper
This white paper by Sterne Kessler Goldstein & Fox PLLC discusses four essential points that manufacturers must be aware of with the Hatch-Waxman Act, which clarified patent extension law.
Fighting generic competition: Strategies for research-based companies
By URCH Publishing
White paper
This white paper from URCH Publishing Ltd. discusses the pros and cons of litigation and other approaches by pharma companies to protect their patent exclusivity and intellectual property in the face of patent expirations.
The Myth of the Anticommons
White paper
The theory called the tragedy of the anticommons was put forth in 1998 and claimed that over-patenting of research in the field of biotechnology was hindering research and development of new innovative treatments. Although no empirical evidence was cited, the theory quickly gained traction. This paper examines the theory from both a theoretical and empirical basis.
NuGenesis SDMS: Improving Data Accessiblity and Intellectual Property Managment
By Waters Laboratory Informatics
Case study
This case study illustrates how the pharmaceutical division of a global healthcare company transitioned to an open access laboratory workflow and improved data and intellectual property management capabilities by implementing Waters Laboratory Informatics solutions, including NuGenesis SDMS, MassLynx, and OpenLynx Application Manager.
Content management streamlines government compliance for pharmaceutical company
By EMC Corp.
Case study
In this case study, EMC Corp.’s content management system streamlines the submission of new drug applications, supports documentation and cuts time to market for approved drugs for Otsuka America Pharmaceutical Co.
Managing strategic assets and speeding time to market
By EMC Corp.
Case study
In this case study, EMC Corp. helps Purdue Pharma LP streamline the production and exchange of content related to regulatory submission processes, connect disparate information systems and move information between those systems.
Market size in innovation: Theory and evidence from the pharmaceutical industry
By Massachusetts Institute of Technology
White paper
This white paper by MIT develops a simple model linking innovation to potential market size, and shows that under a variety of circumstances, greater market size for a particular product, which implies greater sales, spurs faster innovation.
Pharma 2010: The Threshold of Innovation
By IBM Corp.
White paper
This white paper is part of IBM Business Consulting Services' on-going commitment to forward-looking industry and business points of view, and their aim to help companies and industries transform futures.
Accelerating time to market for new drugs
By BroadVision Inc.
White paper
This white paper by BroadVision Inc. explores business-to-business solutions that can help pharmaceutical companies ensure effective collaboration with partners.
Challenge and opportunity on the critical path to new medical products
By FDA Center for Drug Evaluation and Research
White paper
This white paper by the FDA's Center for Drug Evaluation and Research (CDER) analyzes the pipeline problem in innovative medical therapies reaching patients and calls for a joint effort of industry, academia and the FDA to develop solutions.
How Effective Document Management Could Help Accelerate Time to Market
By MasterControl Inc.
White paper
This paper explains why document management is critical throughout the drug development process; examines common challenges pertaining to document control during each phase of the process (pre-clinical, clinical, commercialization, launch and post-market); and offers ways to maximize development time and avoid delays due to poor document management.
